Nicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the recent data showing that plasma can act as a potential alternative to EGFR mutation analysis in the treatment of patients with non-small cell lung cancer, as well as the current demands for the use of liquid biopsies in this type of treatment.
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More